Clinical Trials & Research in Lymphoma
Our patients benefit from treatment by experienced professionals who participate in the clinical trial development of promising new cancer treatments often not yet available at other facilities.Our patients benefit from treatment by experienced professionals who participate in the clinical trial development of promising new cancer treatments often not yet available at other facilities.
Stanford Research Breakthroughs
- The development of rituximab, by Dr. Ronald Levy, the monoclonal anti-CD20 antibody, has changed the treatment of lymphoma worldwide. Stanford Cancer Center physicians and researchers discovered the therapeutic effects of this antibody and have been instrumental in developing its many applications.
- Stanford researchers have validated that an expression of two genes together, one by tumor cells and another by the immune microenvironment, are extremely useful in predicting overall survival in patients with diffuse large B cell lymphoma (DLBCL), the most common form of non-Hodgkin's lymphoma. This finding could result in the first gene-based screen to identify patients who may benefit from immediate treatment with the most aggressive therapies.
- We have led the development of novel targets therapies, such as the oral inhibitor of Bruton tyrosine kinase (Btk), a critical part of the signaling pathway required for B cell growth
Learn more about Lymphoma clinical trials and Cutaneous Lymphoma clinical trials. Please see the Center for Cancer and Blood Diseases at Lucile Packard Children's Hospital at Stanford for pediatric clinical trials.
Trial Administration